STOCK TITAN

Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

Breeze Holdings Acquisition Corp (OTCQX: BRZH) has entered into a definitive agreement to merge with YD Biopharma , a clinical-stage biopharmaceutical company focusing on cancer prevention diagnostics and exosome-based therapeutics. The combined company, with an estimated enterprise value of nearly $700 million, is expected to be listed on the Nasdaq Capital Market by early 2025.

YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer, and is in the process of acquiring licenses for breast cancer detection technology. The company also specializes in ophthalmology cellular drug development and serves as a clinical testing drug supplier for Novartis.

The transaction, approved by both companies' boards, aims to provide YD Biopharma with capital to expand production and continue development, approval, and launch of new technologies. The combined company will be led by YD Biopharma's current management team.

Breeze Holdings Acquisition Corp (OTCQX: BRZH) ha stipulato un accordo definitivo per unire le forze con YD Biopharma, un'azienda biofarmaceutica in fase clinica che si concentra sulla diagnostica per la prevenzione del cancro e sulle terapie basate su esaosomi. La società combinata, con un valore d'impresa stimato di quasi 700 milioni di dollari, dovrebbe essere quotata sul Nasdaq Capital Market entro la fine del 2025.

YD Biopharma ha recentemente ottenuto brevetti, tecnologie e autorizzazioni negli Stati Uniti per la rilevazione chiave della metilazione del cancro al pancreas ed è in procinto di acquisire licenze per una tecnologia di rilevazione del cancro al seno. L'azienda si specializza inoltre nello sviluppo di farmaci cellulari in oftalmologia e funge da fornitore di farmaci per prove cliniche per Novartis.

La transazione, approvata dai consigli di amministrazione di entrambe le aziende, mira a fornire a YD Biopharma il capitale necessario per espandere la produzione e continuare lo sviluppo, l'approvazione e il lancio di nuove tecnologie. La società risultante sarà guidata dall'attuale team dirigenziale di YD Biopharma.

Breeze Holdings Acquisition Corp (OTCQX: BRZH) ha llegado a un acuerdo definitivo para fusionarse con YD Biopharma, una empresa biofarmacéutica en etapa clínica que se centra en diagnósticos de prevención del cáncer y terapias basadas en exosomas. Se espera que la empresa combinada, con un valor empresarial estimado de casi 700 millones de dólares, se cotice en el Nasdaq Capital Market a principios de 2025.

YD Biopharma ha obtenido recientemente patentes, tecnología y autorización en EE. UU. para la detección clave de metilación del cáncer de páncreas, y está en proceso de adquirir licencias para una tecnología de detección del cáncer de mama. La empresa también se especializa en el desarrollo de fármacos celulares en oftalmología y actúa como proveedor de medicamentos para pruebas clínicas para Novartis.

La transacción, aprobada por las juntas de ambas empresas, tiene como objetivo proporcionar a YD Biopharma capital para expandir la producción y continuar el desarrollo, la aprobación y el lanzamiento de nuevas tecnologías. La empresa combinada será dirigida por el actual equipo de gestión de YD Biopharma.

Breeze Holdings Acquisition Corp (OTCQX: BRZH)는 암 예방 진단 및 엑소좀 기반 치료에 집중하는 임상 단계의 생물 제약 회사인 YD Biopharma와 합병하기 위한 확정 계약을 체결했습니다. 7억 달러에 가까운 예상 기업 가치를 지닌 이 회사는 2025년 초까지 Nasdaq Capital Market에 상장될 것으로 보입니다.

YD Biopharma는 최근 췌장암의 핵심 메틸화 탐지에 대한 특허, 기술 및 미국 승인을 획득했으며, 유방암 탐지 기술에 대한 라이선스를 확보하는 과정에 있습니다. 또한, 이 회사는 안과 세포 약물 개발에 전문화되어 있으며 Novartis의 임상 시험 약물 공급업체로 활동하고 있습니다.

양사의 이사회가 승인한 이번 거래는 YD Biopharma에 생산 확장 및 새로운 기술의 개발, 승인 및 출시를 계속할 수 있는 자본을 제공하는 것을 목표로 하고 있습니다. 통합된 회사는 YD Biopharma의 현재 관리 팀이 이끌게 됩니다.

Breeze Holdings Acquisition Corp (OTCQX: BRZH) a conclu un accord définitif pour fusionner avec YD Biopharma, une entreprise biopharmaceutique en phase clinique axée sur le diagnostic de la prévention du cancer et les thérapies basées sur des exosomes. La société combinée, avec une valeur d'entreprise estimée à près de 700 millions de dollars, devrait être cotée sur le Nasdaq Capital Market d'ici début 2025.

YD Biopharma a récemment obtenu des brevets, des technologies et une autorisation aux États-Unis pour la détection clé de la méthylation du cancer du pancréas et est en train d'acquérir des licences pour une technologie de détection du cancer du sein. L'entreprise se spécialise également dans le développement de médicaments cellulaires en ophtalmologie et agit en tant que fournisseur de médicaments pour des essais cliniques pour Novartis.

La transaction, approuvée par les conseils d'administration des deux entreprises, vise à fournir à YD Biopharma le capital nécessaire pour étendre la production et continuer le développement, l'approbation et le lancement de nouvelles technologies. La société combinée sera dirigée par l'équipe de direction actuelle de YD Biopharma.

Breeze Holdings Acquisition Corp (OTCQX: BRZH) hat eine endgültige Vereinbarung zur Fusion mit YD Biopharma getroffen, einem biopharmazeutischen Unternehmen in der klinischen Phase, das sich auf die Diagnostik zur Krebsfrüherkennung und exosombasierte Therapeutika konzentriert. Das kombinierte Unternehmen, das einen geschätzten Unternehmenswert von nahezu 700 Millionen Dollar haben wird, soll bis Anfang 2025 an der Nasdaq Capital Market gelistet werden.

YD Biopharma hat kürzlich Patente, Technologie und eine US-Zulassung zur Kernmetilierungserkennung von Bauchspeicheldrüsenkrebs erhalten und befindet sich im Prozess, Lizenzen für die Erkennung von Brustkrebs zu erwerben. Das Unternehmen ist auch auf die Entwicklung von zellulären Arzneimitteln in der Augenheilkunde spezialisiert und fungiert als Lieferant für klinische Testarzneimittel für Novartis.

Die Transaktion, die von den Vorständen beider Unternehmen genehmigt wurde, zielt darauf ab, YD Biopharma Kapital bereitzustellen, um die Produktion auszubauen und die Entwicklung, Genehmigung und Markteinführung neuer Technologien fortzusetzen. Das kombinierte Unternehmen wird von dem aktuellen Management-Team von YD Biopharma geleitet.

Positive
  • Merger expected to result in Nasdaq Capital Market listing, potentially increasing visibility and liquidity
  • Combined company estimated enterprise value of $694 million
  • YD Biopharma's recent acquisition of patents and technology for pancreatic cancer detection
  • Ongoing process to acquire licenses for breast cancer detection technology
  • Strategic partnerships with Novartis, EG BioMed, and 3D Global Biotech
  • Multi-billion-dollar global market potential for YD Biopharma's solutions
Negative
  • Transaction completion subject to regulatory and stockholder approvals
  • Potential for shareholder dilution due to new capital raising of $15 million
  • Merger not expected to close until early 2025, introducing timing uncertainty

Insights

This merger announcement between Breeze Holdings and YD Biopharma is a significant development with potentially far-reaching implications for investors. The deal values the combined entity at an estimated $694 million enterprise value, which is substantial given Breeze's current market cap of around $49 million.

Key points to consider:

  • YD Biopharma brings a diverse portfolio in cancer diagnostics and eye disease treatments, addressing large markets with high growth potential.
  • Strategic partnerships with Novartis and licensing agreements for proprietary technologies provide validation and competitive advantages.
  • The $15 million in anticipated new capital could accelerate YD Biopharma's R&D and commercialization efforts.
  • Post-merger Nasdaq listing may improve liquidity and access to capital markets.

However, investors should note the extended timeline for closing (early 2025) and potential risks associated with clinical-stage biotech companies. The success of YD Biopharma's technologies in large-scale commercialization remains to be proven.

YD Biopharma's focus on early cancer detection and novel eye disease treatments presents a compelling scientific proposition. Their core methylation detection technology for pancreatic cancer, if proven effective, could be groundbreaking given the typically late diagnosis and poor prognosis of this disease.

The company's multi-pronged approach is noteworthy:

  • Pancreatic and breast cancer diagnostics address critical unmet needs in oncology.
  • Corneal mesenchymal stem cell technology for eye diseases offers a novel therapeutic avenue.
  • Partnerships with established entities like 3D Global Biotech and EG Biomed provide technological depth.

However, the clinical-stage nature of these technologies implies significant regulatory hurdles ahead. Investors should closely monitor clinical trial progress and regulatory milestones. The diverse portfolio may provide multiple shots on goal but also requires substantial resources to develop concurrently.

YD Biopharma is a Clinical-Stage Biopharmaceutical Company Focusing on Cancer Prevention Diagnostics and Seeking to Transform the Treatment of a Wide Spectrum of Diseases

Pro Forma for the Transaction, Combined Company is Expected to Have an Estimated Enterprise Value of Nearly $700 Million

The Proposed Merger is Expected to Close by Early 2025; After Closing, the Combined Company is Expected to be Listed on Nasdaq Capital Market

YD Biopharma has Recently Obtained Patents, Technology, and U.S. Authorization for Core Methylation Detection of Pancreatic Cancer, Along with Entering into an Agreement to Acquire Licenses for Breast Cancer Detection Upon the Closing of the Merger

IRVING, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Breeze Holdings Acquisition Corp. (OTCQX: BRZH, BRZHR, BRZHW) (“Breeze” or the “Company”), a publicly traded special purpose acquisition company, has entered into a definitive agreement to merge with YD Biopharma Limited (“YD Biopharma”), a clinical-stage biopharmaceutical company focusing on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Following the closing, the combined company is expected to be listed on the Nasdaq Capital Market.

Using Technology to Detect Health Problems Early On
YD Biopharma specializes in the biopharmaceutical business and serves as a supplier of drugs and medical materials for clinical trials. In 2015, YD Biopharma was appointed as a clinical testing drug supplier by Novartis and has since expanded its offerings to include development and supply of ancillary products post-launch. YD Biopharma’s mission is to create a cancer-free world through advancements in biotechnology.

More recently, YD Biopharma obtained patent and technology authorization from 3D Global Biotech Inc. (“3D Biotech”) to pioneer the application of corneal mesenchymal stem cells and their exosomes for treating eye diseases. YD Biopharma has introduced new advanced drugs and treatments for conditions such as dry eye disease, glaucoma, and corneal repair. YD Biopharma aims to optimize the treatment market for eye diseases by distribution through pharmacies, optometrists, and other channels.

Earlier this year, YD Biopharma obtained patents, technology and U.S. market authorization from EG Biomed Taiwan for core methylation detection of pancreatic cancer with high sensitivity, specificity and accuracy. This partnership has led to the establishment of an independent laboratory in the U.S. dedicated to pancreatic cancer early detection and monitoring technology that marks a significant expansion of YD Biopharma’s research and development capabilities to collaborate with hospitals, insurance companies and pharmaceutical companies to reach new patients.

YD Biopharma has also recently negotiated related authorizations for breast cancer detection to further expand the Company’s product offerings. YD Biopharma is in the process of acquiring licenses from EG BioMed Taiwan for advanced breast cancer detection technology in the U.S., E.U., and Asia-Pacific that has high sensitivity, specificity and accuracy. The acquisition of the licenses for EG Biomed’s breast cancer detection technology in the U.S., E.U., and Asia-Pacific is expected to be consummated simultaneously with the closing of the merger with Breeze.

Management Commentary
Dr. Ethan Shen, the Founder, Chairman and CEO of YD Biopharma, has an extensive background in the pharmaceutical industry having worked at a well-known global pharmaceutical company. Inspired by his father’s struggle with cancer and subsequent passing, Dr. Shen is dedicated to eradicating cancer and helping people to avoid chronic and painful treatments through early detection.

Dr. Shen stated the following regarding the proposed transaction, “I’m pleased to announce the next phase of our strategy as we embark on a public listing in the U.S. through the proposed business combination with Breeze. Since our founding in 2013, we’ve made significant strides in expanding our capabilities through organic innovation, licensing agreements, and notable strategic partnerships. We have a strategic roadmap in place for accelerated growth and a compelling story to tell in the U.S. market as we aim to deliver health problem detection at an earlier stage than ever before through minimal intervention.”

J. Douglas Ramsey, Ph.D., Chairman and CEO of Breeze, commented, “From day one, it has been our mission at Breeze to find a company with innovative and disruptive technology that has the potential to deliver significant growth to our shareholders. We are highly optimistic about the proposed business combination with YD Biopharma, a company that we believe is a true outlier in the biotech industry with strong growth potential in a variety of healthcare markets. We are working closely with their team to expeditiously close the transaction by early 2025 and move forward with YD Biopharma as a publicly traded company in the U.S.”

YD Biopharma Key Investment Highlights

  • Proven Capabilities Across a Broad Spectrum of Solutions: YD Biopharma has an extensive suite of solutions ranging from ophthalmology cellular drug development to pancreatic and breast cancer diagnostics to nutritional product sales.
  • Notable Strategic Partnerships, Offering Validation and Growth Potential: YD Biopharma is a clinical testing drug supplier for Novartis, a top five global pharmaceutical company, as well as having licensing partnerships with EG BioMed for pancreatic cancer detection and 3D Global Biotech to develop treatment for eye disorders.
  • Proprietary Technology Supported by Licensing Agreements and IP Portfolio: Multi-decade, exclusive licensing agreements and owned, patented technology provides YD Biopharma with significant competitive first-mover advantage in each of its clinical markets.
  • Large and Underserved Markets for Each Solution Showcase Untapped Growth Potential: Multi-billion-dollar global market sizes and high single digit CAGRs over the next decade provide significant growth potential for YD Biopharma’s solutions.
  • Strong Leadership Team with Deep Expertise in Biotech and Finance: YD Biopharma has a founder-led management team with experience in new drug development, medical-grade health product development, pharmacy channel development, and financial management and accounting.

Transaction Overview
Under the terms of the business combination agreement, Breeze and YD Biopharma will each merge into wholly-owned subsidiaries of a newly formed Cayman holding company expected to be named “YD Biopharma Holdings Limited” and is anticipated to be listed on the Nasdaq Capital Market.

Assuming no redemptions, the combined company will have an estimated post-transaction enterprise value of $694 million, consisting of an estimated equity value of $715 million, $21.0 million in cash and no debt. Cash proceeds raised will consist of Breeze’s $10.1 million cash in trust (before redemptions and payment of any transaction expenses) and $15 million in anticipated new capital.

YD Biopharma intends to use the proceeds from the transaction to expand production and continue development, approval and launch of new technologies.

The transaction has been unanimously approved by the boards of directors of both YD Biopharma and Breeze. It is expected to close by early 2025, subject to regulatory and stockholder approvals, and other customary closing conditions. Additional information may be found in the Current Report on Form 8-K that was filed by Breeze Holdings today with the U.S. Securities and Exchange Commission.

Upon completion of the transaction, YD Biopharma will continue to be led by Founder, Chairman, and CEO Dr. Ethan Shen. Wu Cheng-fend will serve as Chief Medical Officer, and May Tsai will serve as Chief Business Officer.

Advisors
ArentFox Schiff LLP and Ogier are acting as legal advisors to YD Biopharma. I-Bankers Securities, Inc. is acting as financial advisor to Breeze Holdings. Woolery & Co. PLLC is acting as legal advisor to Breeze Holdings.

About YD Biopharma
YD Biopharma Limited is a clinical-stage biopharmaceutical company focusing on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. Through continuous effort and innovation, the Company has also become a recognized supplier of clinical trial drugs and has begun developing and supplying post-market auxiliary products.

For more information, please visit www.yd-biopharma.com.

About Breeze Holdings Acquisition Corp.
Breeze Holdings is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses or entities.

Additional Information and Where to Find It
This press release relates to a proposed business combination transaction involving Breeze Holdings and YD Biopharma. In connection with the proposed transaction, a newly-formed Cayman exempted company expected to be named “YD Biopharma Holdings Limited” (“YD Holdings”) intends to file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form F-4 that will include a proxy statement of Breeze and that also will constitute a prospectus of YD Holdings with respect to the ordinary shares of YD Holdings to be issued in the proposed transaction (the “Proxy Statement/Prospectus”). This document is not a substitute for the Proxy Statement/Prospectus. The definitive Proxy Statement/Prospectus (if and when available) will be delivered to Breeze Holdings’ and YD Biopharma’s stockholders. Breeze Holdings may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF BREEZE HOLDINGS AND YD BIOPHARMA AND OTHER INTERESTED PARTIES ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT BREEZE HOLDINGS, YD HOLDINGS, YD BIOPHARMA, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and security holders of Breeze Holdings and YD Biopharma may obtain free copies of the Registration Statement and Proxy Statement/Prospectus (if and when available) and other documents that are filed or will be filed with the SEC by Breeze Holdings through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by Breeze Holdings will be available free of charge at Breeze Holdings Acquisition Corp., 955 W. John Carpenter Fwy., Suite 100-929, Irving, TX 75039, attention: J. Douglas Ramsey.

Participants in the Solicitation
Breeze Holdings, YD Biopharma and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Breeze Holdings and YD Biopharma in respect of the proposed transaction. Information about Breeze Holdings’ directors and executive officers and their ownership of Breeze Holdings common stock is set forth in Breeze Holdings’ filings with the SEC, including its Annual Report on Form 10-K/A for the year ended December 31, 2023 filed with the SEC on April 25, 2024 (the “Annual Report”). To the extent that holdings of Breeze Holdings’ securities have changed since the amounts included in the Annual Report, such changes have been or will be reflected on Statements of Change in Ownership of Form 4 filed with the SEC. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements regarding the anticipated benefits and impact of the proposed transaction on the combined company’s business and future financial and operating results, the anticipated timing of closing of the proposed transaction, the anticipated growth of the industries and markets in which YD Biopharma competes, the success and customer acceptance of YD Biopharma’s product and service offerings and other aspects of YD Biopharma’s operations, plans, objectives, opportunities, expectations or operating results, the expected ownership structure of the combined company and the likelihood and ability of the parties to successfully consummate the proposed transaction. Words such as “may,” “should,” “will,” “believe,” “expect,” “anticipate,” “intend,” “estimated,” “target,” “project,” and similar phrases or words of similar meaning that denote future expectations or intent regarding the combined company’s financial results, operations and other matters are intended to identify forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Such forward-looking statements are based upon the current beliefs and expectations of management and are inherently subject to significant business, economic and competitive risks, uncertainties and other factors, both known and unknown, which are difficult to predict and generally beyond our control and that may cause actual results and the timing of future events to differ materially from the results and timing of future events anticipated by the forward-looking statements in this press release, including but not limited to: (i) the ability of the parties to complete the proposed transaction within the time frame anticipated or at all, which may adversely impact the price of Breeze Holdings’ securities; (ii) the failure to realize the anticipated benefits of the proposed transaction or those benefits taking longer than anticipated to be realized; (iii) the risk that the proposed transaction may not be completed by Breeze Holdings’ business combination deadline and the potential failure to obtain further extensions of the business combination deadline if sought by Breeze Holdings; (iv) the failure to satisfy the conditions to the consummation of the proposed transaction, including the adoption of the definitive merger agreement by the stockholders of Breeze Holdings or YD Biopharma, the receipt of any required governmental or regulatory approvals or the failure to meet the Nasdaq listing standards in connection with the closing of the proposed transaction; (v) the lack of a third party valuation in determining whether or not to pursue the proposed transaction; (vi) the occurrence of any event, change or other circumstance that could give rise to the termination of the definitive merger agreement; (vii) the impact of the COVID-19 pandemic or related governmental or regulatory orders ; (viii) the effect of the announcement or pendency of the proposed transaction on YD Biopharma’s business relationships, performance and business generally; (ix) risks that the proposed transaction disrupts current plans and operations of YD Biopharma and any potential difficulties in YD Biopharma employee retention as a result of the proposed transaction; (x) the outcome of any legal proceedings that may be instituted against YD Biopharma or Breeze Holdings related to the definitive merger agreement or the proposed transaction or any product liability or regulatory lawsuits or proceedings relating to YD Biopharma’s products or services; (xi) the ability to maintain the listing of YD Holdings’ securities on the Nasdaq Capital Market after the closing of the proposed transaction; (xii) potential volatility in the price of Breeze Holdings’ securities due to a variety of factors, including changes in the competitive and highly regulated industries in which YD Biopharma operates, variations in performance across competitors, changes in laws and regulations affecting YD Biopharma’s business, and changes in the combined company’s capital structure; (xiii) the ability to implement business plans, identify and realize additional opportunities and achieve forecasts and other expectations after the completion of the proposed transaction; (xiv) the risk of downturns and the possibility of rapid change in the highly competitive industries in which YD Biopharma operates or the markets that YD Biopharma targets; (xv) the inability of YD Biopharma and its current and future collaborators to successfully develop and commercialize YD Biopharma’s products and services in the expected time frame or at all; (xvi) the risk that the combined company may never achieve or sustain profitability or may need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; and (xvii) the costs of the proposed transaction. The forward-looking statements contained in this press release are also subject to additional risks, uncertainties and factors, including those described in Breeze Holdings’ most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and other documents filed or to be filed with the SEC by Breeze Holdings from time to time. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as projected financial information and other information are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. The forward-looking statements included in this press release are made only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof. Forecasts and estimates regarding YD Biopharma’s industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Annualized, pro forma, projected and estimated numbers are used for illustrative purposes only, are not forecasts and may not reflect actual results.

No Offer or Solicitation
This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities in respect of the proposed transaction and is not a substitute for the Proxy Statement/Prospectus or any other document that Breeze Holdings may file with the SEC or send to Breeze Holdings’ or YD Biopharma’s stockholders in connection with the proposed transaction. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Contacts:

YD Biopharma Limited
Bob Chiu
bobc95@udn-pharm.com

Breeze Holdings Acquisition Corp.
Investor Relations
Cody Slach and Cody Cree
Gateway Group

(949) 574-3860
BREZ@gateway-grp.com


FAQ

What is the estimated enterprise value of the combined company after the merger between Breeze Holdings (BREZ) and YD Biopharma?

The combined company is expected to have an estimated enterprise value of nearly $700 million after the merger.

When is the merger between Breeze Holdings (BREZ) and YD Biopharma expected to close?

The proposed merger is expected to close by early 2025, subject to regulatory and stockholder approvals, and other customary closing conditions.

What recent technological acquisitions has YD Biopharma made before the merger with Breeze Holdings (BREZ)?

YD Biopharma has recently obtained patents, technology, and U.S. authorization for core methylation detection of pancreatic cancer. It is also in the process of acquiring licenses for breast cancer detection technology.

How will the proceeds from the merger with Breeze Holdings (BREZ) be used by YD Biopharma?

YD Biopharma intends to use the proceeds from the transaction to expand production and continue development, approval, and launch of new technologies.

Breeze Holdings Acquisition Corp.

NASDAQ:BREZ

BREZ Rankings

BREZ Latest News

BREZ Stock Data

48.97M
4.30M
83.63%
21.2%
0.1%
Shell Companies
Blank Checks
United States of America
IRVING